TG Therapeutics TGTX Debt Issuance Cost Amortization
Debt Issuance Cost Amortization at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's debt issuance cost amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's debt issuance cost amortization?
- TG Therapeutics (TGTX) reported debt issuance cost amortization of $285K in Q1 2026.
- How has TG Therapeutics's debt issuance cost amortization changed year-over-year?
- TG Therapeutics's debt issuance cost amortization decreased by 6.3% year-over-year, from $304K to $285K.
- What is the long-term trend for TG Therapeutics's debt issuance cost amortization?
- Over 4 years (2021 to 2025), TG Therapeutics's debt issuance cost amortization has grown at a 1.4% compound annual growth rate (CAGR), from $1.15M to $1.22M.
- What does debt issuance cost amortization mean?
- Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).